Table 4.

Outcome after salvage lymph node dissection/salvage lymph node radiotherapy

	SLND cohort (n = 33)	SLNRT cohort (n = 67)	p-value
Median follow-up (months)	17 (6–53)	31 (3–56)	0.027
Posttreatment PSA (ng/ml)	0.47 (<0.03–9.61)	0.05 (<0.03–19.0)	0.003
PSA at last follow-up (ng/ml)
Median PSA (range)	2.50 (<0.03–68.0)	0.05 (<0.03–268)	0.025
PSA ≤0.1 ng/ml	7 (21%)	46 (69%)	0.001
PSA ≤0.2 ng/ml	10 (30%)	50 (75%)	0.001
PSA at last follow-up without ADT (ng/ml)	n = 25	n = 42
Median PSA	1.21 (<0.03–13.0)	0.06 (<0.03–268)	0.02
PSA ≤0.1 ng/ml	5 (20%)	32 (76%)	0.001
PSA ≤0.2 ng/ml	7 (28%)	34 (81%)	0.001
Secondary treatment (ADT, RT, sx)	13 (39%)	10 (15%)	0.011
Clinical progress
Distant metastases	17 (52%)	14 (21%)	0.002
Death	0	3	0.549
Tumour-related	0	1	1.0

SLND salvage lymph node dissection, SLNRT salvage lymph node radiotherapy, ADT androgen deprivation therapy, PSA prostate specific antigen, RT radiotherapy, sx surgery